CJC-1295 and the Ipamorelin Stack: Filipino User's Guide to Growth Hormone Peptides

The CJC-1295 plus ipamorelin stack is the most-discussed growth-hormone peptide protocol in Filipino biohacker, anti-ageing, and bodybuilding communities. The pairing combines a GHRH analogue (CJC-1295) with a GHRP (ipamorelin) to produce synergistic growth-hormone release that exceeds either peptide alone. The protocol is widely shared across forums and private messaging groups, and the supply chain in the Philippines now includes both branded research peptides and significant grey-market product.

This guide covers what CJC-1295 actually is, the critical with-DAC versus without-DAC distinction that confuses most Filipino users, the standard stack protocol with ipamorelin, the timing and dosing patterns, and the purity and quality issues that affect grey-market CJC-1295 specifically.

For the deep dive on ipamorelin alone, see ipamorelin. For the comparison with actual recombinant HGH, see HGH peptides vs real HGH. For the broader research-peptide pillar, see our BPC-157 complete guide.

What CJC-1295 is

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the natural hypothalamic peptide that signals the pituitary gland to produce and release growth hormone. The native GHRH molecule has a very short half-life (a few minutes), which makes it impractical as a therapeutic. CJC-1295 modifies the GHRH structure to produce a longer-acting molecule that maintains GHRH activity over hours to days.

There are two distinct forms of CJC-1295 sold in the research-peptide market:

CJC-1295 without DAC (also called Mod GRF 1-29 or modified GRF 1-29):

• Modified GHRH 1-29 fragment with stability-enhancing amino acid substitutions.
• Half-life: approximately 30 minutes.
• Dosing: multiple times per day.
• Pulsatile pattern: produces GH pulses similar to natural physiology.

CJC-1295 with DAC (drug-affinity complex):

• Same modified GHRH 1-29 fragment with an added DAC tag that binds to circulating albumin.
• Half-life: approximately 8 days.
• Dosing: 1 to 2 times per week.
• Sustained pattern: produces continuous GHRH stimulation rather than pulses.

The two forms are pharmacologically different and produce different physiological effects. The marketing literature often conflates them. Filipino users buying "CJC-1295" should know which form they actually have.

Why the with-DAC versus without-DAC distinction matters

The clinical and physiological difference:

Without DAC (Mod GRF 1-29) preserves natural pulsatile GH release patterns. The pituitary somatotrophs receive periodic GHRH stimulation, release GH in pulses, and have time to recover between pulses. This more closely mimics natural GH physiology.

With DAC produces continuous GHRH stimulation through the long half-life. The pituitary somatotrophs are kept in an activated state continuously. GH release is elevated more constantly. The body's natural pulsatile pattern is overridden.

Theoretical implications:

• Mod GRF 1-29 with multi-daily dosing plus a GHRP is closer to natural physiology and may have a more favourable long-term safety profile.
• CJC-1295 with DAC is more convenient (twice weekly versus multi-daily) but produces sustained elevation that some endocrinologists consider less physiological.

Most established Filipino biohacker protocols use Mod GRF 1-29 (without DAC) paired with ipamorelin. CJC-1295 with DAC is used less commonly but still appears in some protocols.

The standard CJC-1295 + ipamorelin stack

Standard protocol for the without-DAC version:

• CJC-1295 without DAC (Mod GRF 1-29): 100 to 300 mcg per dose.
• Ipamorelin: 100 to 300 mcg per dose.
• Frequency: 2 to 3 times per day, ideally pre-bed, pre-workout, and upon waking.
• Timing: empty stomach if possible (food can blunt GH release).
• Cycle: 8 to 16 weeks, evaluated by IGF-1 bloodwork and subjective effects.
• Off-period: 4 to 8 weeks between cycles.

Standard protocol for the with-DAC version:

• CJC-1295 with DAC: 1 to 2 mg per week, single subcutaneous injection.
• Ipamorelin: 100 to 300 mcg, 1 to 3 times per day.
• Cycle: similar duration, similar evaluation pattern.

The pair injection (Mod GRF 1-29 + ipamorelin together) is the most common practical pattern. Both peptides are reconstituted with bacteriostatic water, drawn into a single insulin syringe, and injected together at each dosing time.

Dose timing and pulsatile GH release

GH is released naturally in pulses, with the largest pulses during the first 1 to 2 hours of deep sleep. The peptide protocol works with this physiology:

Pre-bed dose (most important):

• Inject 30 to 60 minutes before sleep.
• Empty stomach for 2+ hours before injection.
• The peptide-induced pulse aligns with natural sleep-onset GH release for maximal effect.

Pre-workout dose (optional):

• Inject 30 to 60 minutes before training.
• May enhance training response and recovery.
• Avoid if it causes fatigue during training.

Upon-waking dose (optional):

• Inject upon waking, before breakfast.
• Adds an additional GH pulse during the daytime trough period.

For Filipino users running 2-times-per-day, pre-bed plus pre-workout is the most common pattern. For 3-times-per-day, add the upon-waking dose.

Reconstitution and storage

CJC-1295 vials typically contain 2 to 5 mg of lyophilised peptide. Standard reconstitution:

• Add 2 mL of bacteriostatic water to a 2 mg vial → 1000 mcg/mL concentration.
• Add 2 mL to a 5 mg vial → 2500 mcg/mL concentration.

Insulin syringe measurement (1 mL = 100 units):

• 100 mcg dose at 1000 mcg/mL: 10 units.
• 200 mcg dose at 1000 mcg/mL: 20 units.
• 300 mcg dose at 1000 mcg/mL: 30 units.

Storage:

• Lyophilised vials: stable at room temperature short-term, refrigerated for longer storage.
• Reconstituted vials: refrigerated, used within 2 to 4 weeks.
• Avoid freeze-thaw cycles.

For the practical reconstitution and injection technique, see how to inject tirzepatide safely.

What the evidence shows

The peer-reviewed evidence base for CJC-1295 is limited. Most of what is known comes from:

1. CJC-1295 with DAC clinical trials conducted by the original developer in the early 2000s for adult growth-hormone deficiency.
2. GHRH analogue research more broadly applied to CJC-1295 by extension.
3. Anecdotal reports from biohacker, bodybuilding, and anti-ageing communities running multi-month protocols.

What the evidence supports:

• GHRH analogues including CJC-1295 stimulate GH release at clinically meaningful magnitudes.
• Combined GHRH + GHRP produces synergistic effect larger than either alone.
• IGF-1 increases over weeks of consistent protocol.
• Bone turnover marker changes in some studies.

What the evidence does not strongly support:

• Significant body-composition changes as the primary effect. Modest at best.
• Anti-ageing claims about lifespan, organ function, or cognitive performance.
• Therapeutic equivalence to recombinant HGH for clinical GH deficiency. The peptide approach produces different and generally smaller effects.

Purity and quality issues with grey-market CJC-1295

CJC-1295 is one of the more variable-quality peptides in the grey-market supply. Independent laboratory analysis has documented:

1. Wrong-form substitution: vials labelled as CJC-1295 with DAC actually containing CJC-1295 without DAC, or vice versa. The half-life and dosing implications are dramatically different. A user dosing without-DAC weekly is producing very little effect; a user dosing with-DAC daily is over-dosing significantly.
2. Underdosed product at 30 to 70% of label.
3. Degraded product from improper storage or shipping.
4. Wrong-peptide substitution with cheaper GHRH analogues or inactive peptides.
5. High endotoxin or microbial contamination from poor sterile manufacturing.

The wrong-form substitution is the most consequential pattern because the user's protocol math depends on which form is in the vial. The visual product is similar across both forms.

Lab verification for CJC-1295

Lumen Labs runs the analytical pathway on submitted CJC-1295 vials:

• HPLC purity: percent peak area at the CJC-1295 absorbance wavelength.
• LC-MS identity: molecular mass match. Mod GRF 1-29 has mass 3367.9 Da; CJC-1295 with DAC has mass 3647.3 Da. The masses are distinct, allowing clear differentiation between the two forms.
• Quantitation: actual milligrams per vial against label claim.
• Optional endotoxin (LAL) and microbial limits (USP 61): contamination assessment.

The output is a certificate of analysis confirming which form of CJC-1295 is present, at what concentration, and whether contamination is within acceptable limits.

Side effects and safety

Common reported side effects:

• Mild headache, particularly in the first week.
• Slight flushing.
• Fatigue or grogginess in some users.
• Injection-site reactions.
• Numbness or tingling (uncommon).
• Water retention at higher doses.

Less common:

• Sleep disturbance (sometimes vivid dreams).
• Mood changes.
• Carpal tunnel-like symptoms with sustained protocols.

Theoretical long-term concerns:

• Insulin resistance with sustained GH elevation.
• Acromegaly-like effects with very long high-dose use (uncommon at typical protocols).
• Cancer concerns related to GH and IGF-1 (theoretical).

Contraindications:

• Active malignancy.
• Diabetic retinopathy.
• Pregnancy and breastfeeding.
• Active pituitary disease.

Bottom line on CJC-1295 for Filipinos

The CJC-1295 + ipamorelin stack is the established protocol for growth-hormone secretagogue use in Filipino communities. The mechanism is sound; the effect is modest. Expect measurable IGF-1 increases, slow improvements in recovery and body composition, and tolerability allowing multi-month protocols.

The with-DAC versus without-DAC distinction matters more than most Filipino users realise. Confirm which form is in your vial through lab verification before designing your protocol.

For Filipino users on growth-hormone peptide protocols, the verification step converts label claim into measured data. Lumen Labs runs the analytical pathway as the Philippine peer to an established international peptide-testing laboratory (Czechia) and another international laboratory (USA).

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. CJC-1295 is not FDA Philippines registered for human use; it is a research peptide. Consult a qualified Philippine licensed physician before any peptide use.